[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fuPjCfEm-kfxTfhwPlqXcrZ-Qn0R7K8lL-BRF6XQGmjc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Cambridge University Hospitals NHS Foundation Trust",[4],164,false,30,21,181543,15,96,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Cardiovascular Diseases",10,{"name":18,"count":19},"Breast Cancer",9,{"name":21,"count":22},"Prostate Cancer",6,{"name":24,"count":25},"Covid19",4,{"name":27,"count":25},"COVID-19",{"name":29,"count":25},"Microscopic Polyangiitis",{"name":31,"count":25},"Hypertension",{"name":33,"count":25},"Stroke",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03150576","Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and\u002For Germline BRCA Positive Breast Cancer","2024-06","Olaparib",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05975554","The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.","2025-02-01","Interleukin-2 [IL-2]",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT04573803","Pharmacological Management of Seizures Post Traumatic Brain Injury","2026-03-01","Phenytoin Sodium",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT04631471","Regeneration in Cervical Degenerative Myelopathy","2026-09-01","Ibudilast",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT07364175","A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults","2027-01","Tirzepatide",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07483801","DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies","2027-04","semaglutide",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06427694","Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study","2027-04-30","Aldesleukin",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05093231","Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer","2027-07-31","Pembrolizumab",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT07157735","A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease","2027-08","dapansutrile",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT07610538","Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells","2028-11-01","Interleukin-2",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,128,146,187,209,227,251,269,287,309,333,374,406,424,442,466,518,556,583,601,628,646,674,692,710,728,793,851,885,907,933,951,977,995,1020,1038,1056,1074,1092,1110,1128,1146,1164,1182,1200,1227,1245,1263,1286,1304,1330,1356,1374,1392,1416,1439,1472,1490,1508,1526,1560,1585,1610,1637,1655,1673,1698,1716,1734,1752,1779,1797,1815,1841,1866,1890,1916,1934,1952,1970,1988,2006,2024,2053,2076,2107,2125,2143,2161,2179,2197,2219,2237,2261,2287,2309,2333,2360,2388,2406,2424,2442,2467,2485,2516,2546,2564,2582,2600,2618,2636,2654,2683,2701,2726,2744,2762,2788,2806,2833,2851],{"intervention":59,"totalTrials":94,"cells":95},2,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":116},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":115,"soonestReadout":63},[107],{"nctId":61,"briefTitle":62,"status":108,"phases":109,"primaryCompletion":63,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":114},"NOT_YET_RECRUITING",[90],"2028-04","2026-03",112,[15],[64,59],1,{"trials":117,"activeCount":115,"soonestReadout":58},[118],{"nctId":56,"briefTitle":57,"status":119,"phases":120,"primaryCompletion":58,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":126},"RECRUITING",[91],"2029-01","2026-01",60,[31,125],"Obesity & Overweight",[59,127],"Anti-Hypertensive medications",{"intervention":64,"totalTrials":115,"cells":129},{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":136,"PHASE4":138,"NA":144},{"trials":131,"activeCount":98},[],{"trials":133,"activeCount":98},[],{"trials":135,"activeCount":98},[],{"trials":137,"activeCount":98},[],{"trials":139,"activeCount":115,"soonestReadout":63},[140],{"nctId":61,"briefTitle":62,"status":108,"phases":141,"primaryCompletion":63,"completion":110,"start":111,"enrollment":112,"conditions":142,"interventions":143},[90],[15],[64,59],{"trials":145,"activeCount":98},[],{"intervention":39,"totalTrials":147,"cells":148},3,{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":164,"PHASE3":173,"PHASE4":183,"NA":185},{"trials":150,"activeCount":98},[],{"trials":152,"activeCount":98},[153],{"nctId":154,"briefTitle":155,"status":156,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":162},"NCT02324998","Study of Olaparib (± Degarelix) Given to Men With Intermediate\u002FHigh Risk Prostate Cancer Before Prostatectomy","COMPLETED",[87],"2019-05","2016-12",20,[21],[39,163],"Degarelix",{"trials":165,"activeCount":115,"soonestReadout":73},[166],{"nctId":71,"briefTitle":72,"status":119,"phases":167,"primaryCompletion":73,"completion":168,"start":169,"enrollment":160,"conditions":170,"interventions":172},[88],"2028-01-01","2025-02-26",[171],"Pancreatic Cancer",[74,39],{"trials":174,"activeCount":115,"soonestReadout":38},[175],{"nctId":36,"briefTitle":37,"status":119,"phases":176,"primaryCompletion":38,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":181},[88,89],"2034-06","2016-05",780,[18],[39,182],"Paclitaxel and Carboplatin",{"trials":184,"activeCount":98},[],{"trials":186,"activeCount":98},[],{"intervention":54,"totalTrials":115,"cells":188},{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":205,"NA":207},{"trials":190,"activeCount":98},[],{"trials":192,"activeCount":98},[],{"trials":194,"activeCount":98},[],{"trials":196,"activeCount":115,"soonestReadout":53},[197],{"nctId":51,"briefTitle":52,"status":119,"phases":198,"primaryCompletion":53,"completion":53,"start":199,"enrollment":200,"conditions":201,"interventions":204},[89],"2021-12-22",400,[202,203],"Myelopathy","Spinal Cord Diseases",[54],{"trials":206,"activeCount":98},[],{"trials":208,"activeCount":98},[],{"intervention":182,"totalTrials":115,"cells":210},{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":223,"NA":225},{"trials":212,"activeCount":98},[],{"trials":214,"activeCount":98},[],{"trials":216,"activeCount":98},[],{"trials":218,"activeCount":115,"soonestReadout":38},[219],{"nctId":36,"briefTitle":37,"status":119,"phases":220,"primaryCompletion":38,"completion":177,"start":178,"enrollment":179,"conditions":221,"interventions":222},[88,89],[18],[39,182],{"trials":224,"activeCount":98},[],{"trials":226,"activeCount":98},[],{"intervention":49,"totalTrials":115,"cells":228},{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":235,"PHASE4":247,"NA":249},{"trials":230,"activeCount":98},[],{"trials":232,"activeCount":98},[],{"trials":234,"activeCount":98},[],{"trials":236,"activeCount":115,"soonestReadout":48},[237],{"nctId":46,"briefTitle":47,"status":108,"phases":238,"primaryCompletion":48,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":245},[89],"2028-03-01","2021-03-01",1649,[243,244],"Traumatic Brain Injury","Post Traumatic Seizures",[49,246],"Levetiracetam",{"trials":248,"activeCount":98},[],{"trials":250,"activeCount":98},[],{"intervention":246,"totalTrials":115,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":265,"NA":267},{"trials":254,"activeCount":98},[],{"trials":256,"activeCount":98},[],{"trials":258,"activeCount":98},[],{"trials":260,"activeCount":115,"soonestReadout":48},[261],{"nctId":46,"briefTitle":47,"status":108,"phases":262,"primaryCompletion":48,"completion":239,"start":240,"enrollment":241,"conditions":263,"interventions":264},[89],[243,244],[49,246],{"trials":266,"activeCount":98},[],{"trials":268,"activeCount":98},[],{"intervention":74,"totalTrials":115,"cells":270},{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":281,"PHASE4":283,"NA":285},{"trials":272,"activeCount":98},[],{"trials":274,"activeCount":98},[],{"trials":276,"activeCount":115,"soonestReadout":73},[277],{"nctId":71,"briefTitle":72,"status":119,"phases":278,"primaryCompletion":73,"completion":168,"start":169,"enrollment":160,"conditions":279,"interventions":280},[88],[171],[74,39],{"trials":282,"activeCount":98},[],{"trials":284,"activeCount":98},[],{"trials":286,"activeCount":98},[],{"intervention":79,"totalTrials":115,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":303,"PHASE4":305,"NA":307},{"trials":290,"activeCount":98},[],{"trials":292,"activeCount":98},[],{"trials":294,"activeCount":115,"soonestReadout":78},[295],{"nctId":76,"briefTitle":77,"status":119,"phases":296,"primaryCompletion":78,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":302},[88],"2028-02","2026-02-02",36,[301],"Parkinson Disease",[79],{"trials":304,"activeCount":98},[],{"trials":306,"activeCount":98},[],{"trials":308,"activeCount":98},[],{"intervention":310,"totalTrials":115,"cells":311},"Apalutamide Oral Tablet [Erleada]",{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":327,"PHASE4":329,"NA":331},{"trials":313,"activeCount":98},[],{"trials":315,"activeCount":98},[],{"trials":317,"activeCount":115,"soonestReadout":322},[318],{"nctId":319,"briefTitle":320,"status":119,"phases":321,"primaryCompletion":322,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":326},"NCT05191680","TherApeutics in Early ProState Cancer (TAPS02)",[88],"2029-10","2023-04-24",90,[21],[310],{"trials":328,"activeCount":98},[],{"trials":330,"activeCount":98},[],{"trials":332,"activeCount":98},[],{"intervention":69,"totalTrials":147,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":360,"PHASE4":362,"NA":364},{"trials":336,"activeCount":98},[],{"trials":338,"activeCount":98},[],{"trials":340,"activeCount":98},[341,351],{"nctId":342,"briefTitle":343,"status":156,"phases":344,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":350},"NCT02265809","Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes",[87,88],"2016-05-26","2014-10-03",41,[349],"Type 1 Diabetes",[69],{"nctId":352,"briefTitle":353,"status":156,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":359},"NCT01827735","Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2",[87,88],"2014-05","2013-03",40,[349],[69],{"trials":361,"activeCount":98},[],{"trials":363,"activeCount":98},[],{"trials":365,"activeCount":115,"soonestReadout":68},[366],{"nctId":66,"briefTitle":67,"status":119,"phases":367,"primaryCompletion":68,"completion":368,"start":369,"enrollment":123,"conditions":370,"interventions":372},[],"2030-02-11","2024-06-01",[371],"Acute Coronary Syndromes",[69,373],"Dextrose 5% in water",{"intervention":44,"totalTrials":94,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":390,"PHASE4":392,"NA":394},{"trials":377,"activeCount":98},[],{"trials":379,"activeCount":98},[],{"trials":381,"activeCount":98},[382],{"nctId":383,"briefTitle":384,"status":156,"phases":385,"primaryCompletion":386,"completion":386,"start":387,"enrollment":123,"conditions":388,"interventions":389},"NCT04241601","Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY",[88],"2023-01-25","2020-08-05",[371],[44],{"trials":391,"activeCount":98},[],{"trials":393,"activeCount":98},[],{"trials":395,"activeCount":115,"soonestReadout":43},[396],{"nctId":41,"briefTitle":42,"status":397,"phases":398,"primaryCompletion":43,"completion":399,"start":400,"enrollment":8,"conditions":401,"interventions":405},"ACTIVE_NOT_RECRUITING",[91],"2025-09-01","2023-08-26",[402,403,404],"TIA","Carotid Artery Plaque","Carotid Atherosclerosis",[44],{"intervention":373,"totalTrials":115,"cells":407},{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":414,"PHASE4":416,"NA":418},{"trials":409,"activeCount":98},[],{"trials":411,"activeCount":98},[],{"trials":413,"activeCount":98},[],{"trials":415,"activeCount":98},[],{"trials":417,"activeCount":98},[],{"trials":419,"activeCount":115,"soonestReadout":68},[420],{"nctId":66,"briefTitle":67,"status":119,"phases":421,"primaryCompletion":68,"completion":368,"start":369,"enrollment":123,"conditions":422,"interventions":423},[],[371],[69,373],{"intervention":127,"totalTrials":115,"cells":425},{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":427,"activeCount":98},[],{"trials":429,"activeCount":98},[],{"trials":431,"activeCount":98},[],{"trials":433,"activeCount":98},[],{"trials":435,"activeCount":98},[],{"trials":437,"activeCount":115,"soonestReadout":58},[438],{"nctId":56,"briefTitle":57,"status":119,"phases":439,"primaryCompletion":58,"completion":121,"start":122,"enrollment":123,"conditions":440,"interventions":441},[91],[31,125],[59,127],{"intervention":84,"totalTrials":115,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":452,"NA":454},{"trials":445,"activeCount":98},[],{"trials":447,"activeCount":98},[],{"trials":449,"activeCount":98},[],{"trials":451,"activeCount":98},[],{"trials":453,"activeCount":98},[],{"trials":455,"activeCount":115,"soonestReadout":83},[456],{"nctId":81,"briefTitle":82,"status":119,"phases":457,"primaryCompletion":83,"completion":458,"start":459,"enrollment":460,"conditions":461,"interventions":465},[91],"2028-12-01","2026-03-31",24,[462,463,464],"Coronary Artery Disease","Myocardial Infarction (MI)","CABG",[84,84],{"intervention":467,"totalTrials":147,"cells":468},"capecitabine",{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":492,"PHASE4":494,"NA":516},{"trials":470,"activeCount":98},[],{"trials":472,"activeCount":98},[],{"trials":474,"activeCount":98},[475],{"nctId":476,"briefTitle":477,"status":156,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":485},"NCT00602082","Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors",[88],"2009-12","2005-08",84,[483,484],"Gastrointestinal Carcinoid Tumor","Islet Cell Tumor",[467,486,487,488,489,490,491],"cisplatin","streptozocin","DNA analysis","RNA analysis","protein analysis","proteomic profiling",{"trials":493,"activeCount":98},[],{"trials":495,"activeCount":98},[496,508],{"nctId":497,"briefTitle":498,"status":499,"phases":500,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":507},"NCT00871273","Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma","TERMINATED",[90],"2013-10","2014-10","2009-11",13,[506],"Adenocarcinoma of the Stomach",[467],{"nctId":509,"briefTitle":510,"status":156,"phases":511,"primaryCompletion":512,"completion":512,"start":503,"enrollment":504,"conditions":513,"interventions":515},"NCT00854477","Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma",[90],"2012-08",[514],"Pancreatic Adenocarcinoma",[467],{"trials":517,"activeCount":98},[],{"intervention":519,"totalTrials":94,"cells":520},"Alemtuzumab",{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":538,"PHASE4":540,"NA":554},{"trials":522,"activeCount":98},[],{"trials":524,"activeCount":98},[],{"trials":526,"activeCount":98},[527],{"nctId":528,"briefTitle":529,"status":499,"phases":530,"primaryCompletion":531,"completion":532,"start":533,"enrollment":357,"conditions":534,"interventions":536},"NCT01712945","Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis",[87,88],"2017-08","2017-10","2012-06",[535],"Multiple Sclerosis",[537,519],"Palifermin",{"trials":539,"activeCount":98},[],{"trials":541,"activeCount":98},[542],{"nctId":543,"briefTitle":544,"status":545,"phases":546,"primaryCompletion":547,"completion":547,"start":548,"enrollment":460,"conditions":549,"interventions":553},"NCT01405807","Alemtuzumab for ANCA Associated Refractory Vasculitis","UNKNOWN",[90],"2014-03","2011-02",[550,29,551,552],"Vasculitis","Granulomatosis With Polyangiitis","Wegener's",[519],{"trials":555,"activeCount":98},[],{"intervention":557,"totalTrials":115,"cells":558},"Lisinopril",{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":565,"PHASE4":567,"NA":581},{"trials":560,"activeCount":98},[],{"trials":562,"activeCount":98},[],{"trials":564,"activeCount":98},[],{"trials":566,"activeCount":98},[],{"trials":568,"activeCount":98},[569],{"nctId":570,"briefTitle":571,"status":156,"phases":572,"primaryCompletion":573,"completion":573,"start":574,"enrollment":575,"conditions":576,"interventions":577},"NCT02847338","Comparison of Optimal Hypertension Regimens",[90],"2023-10","2016-11",940,[31],[578,557,579,580],"Amlodipine","Amiloride","Chlortalidone",{"trials":582,"activeCount":98},[],{"intervention":579,"totalTrials":115,"cells":584},{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":591,"PHASE4":593,"NA":599},{"trials":586,"activeCount":98},[],{"trials":588,"activeCount":98},[],{"trials":590,"activeCount":98},[],{"trials":592,"activeCount":98},[],{"trials":594,"activeCount":98},[595],{"nctId":570,"briefTitle":571,"status":156,"phases":596,"primaryCompletion":573,"completion":573,"start":574,"enrollment":575,"conditions":597,"interventions":598},[90],[31],[578,557,579,580],{"trials":600,"activeCount":98},[],{"intervention":602,"totalTrials":115,"cells":603},"Ravulizumab",{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":610,"PHASE4":612,"NA":626},{"trials":605,"activeCount":98},[],{"trials":607,"activeCount":98},[],{"trials":609,"activeCount":98},[],{"trials":611,"activeCount":98},[],{"trials":613,"activeCount":98},[614],{"nctId":615,"briefTitle":616,"status":545,"phases":617,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":624},"NCT04390464","mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)",[90],"2021-05-07","2022-05-01","2020-05-08",1167,[623],"COVID19",[602,625],"Baricitinib",{"trials":627,"activeCount":98},[],{"intervention":625,"totalTrials":115,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":636,"PHASE4":638,"NA":644},{"trials":631,"activeCount":98},[],{"trials":633,"activeCount":98},[],{"trials":635,"activeCount":98},[],{"trials":637,"activeCount":98},[],{"trials":639,"activeCount":98},[640],{"nctId":615,"briefTitle":616,"status":545,"phases":641,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":642,"interventions":643},[90],[623],[602,625],{"trials":645,"activeCount":98},[],{"intervention":647,"totalTrials":115,"cells":648},"0.9% Sodium-chloride",{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":655,"PHASE4":657,"NA":672},{"trials":650,"activeCount":98},[],{"trials":652,"activeCount":98},[],{"trials":654,"activeCount":98},[],{"trials":656,"activeCount":98},[],{"trials":658,"activeCount":98},[659],{"nctId":660,"briefTitle":661,"status":156,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":16,"conditions":665,"interventions":668},"NCT04307797","Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes",[90],"2022-10-07","2022-01-18",[666,667],"Type 2 Diabetes","Obesity",[647,669,670,647,669,671],"Exenatide (50ng\u002Fmin for 30 minutes loading followed by 25ng\u002Fmin maintenance) and glucagon 12.5ng\u002Fkg\u002Fmin","Glucagon 12.5ng\u002Fkg\u002Fmin and 0.9% saline","Glucagon 12.5ng\u002Fkg\u002Fmin",{"trials":673,"activeCount":98},[],{"intervention":669,"totalTrials":115,"cells":675},{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":682,"PHASE4":684,"NA":690},{"trials":677,"activeCount":98},[],{"trials":679,"activeCount":98},[],{"trials":681,"activeCount":98},[],{"trials":683,"activeCount":98},[],{"trials":685,"activeCount":98},[686],{"nctId":660,"briefTitle":661,"status":156,"phases":687,"primaryCompletion":663,"completion":663,"start":664,"enrollment":16,"conditions":688,"interventions":689},[90],[666,667],[647,669,670,647,669,671],{"trials":691,"activeCount":98},[],{"intervention":670,"totalTrials":115,"cells":693},{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":700,"PHASE4":702,"NA":708},{"trials":695,"activeCount":98},[],{"trials":697,"activeCount":98},[],{"trials":699,"activeCount":98},[],{"trials":701,"activeCount":98},[],{"trials":703,"activeCount":98},[704],{"nctId":660,"briefTitle":661,"status":156,"phases":705,"primaryCompletion":663,"completion":663,"start":664,"enrollment":16,"conditions":706,"interventions":707},[90],[666,667],[647,669,670,647,669,671],{"trials":709,"activeCount":98},[],{"intervention":671,"totalTrials":115,"cells":711},{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":720,"NA":726},{"trials":713,"activeCount":98},[],{"trials":715,"activeCount":98},[],{"trials":717,"activeCount":98},[],{"trials":719,"activeCount":98},[],{"trials":721,"activeCount":98},[722],{"nctId":660,"briefTitle":661,"status":156,"phases":723,"primaryCompletion":663,"completion":663,"start":664,"enrollment":16,"conditions":724,"interventions":725},[90],[666,667],[647,669,670,647,669,671],{"trials":727,"activeCount":98},[],{"intervention":729,"totalTrials":25,"cells":730},"cyclophosphamide",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":789,"NA":791},{"trials":732,"activeCount":98},[],{"trials":734,"activeCount":98},[],{"trials":736,"activeCount":98},[],{"trials":738,"activeCount":98},[739,750,765,778],{"nctId":740,"briefTitle":741,"status":156,"phases":742,"primaryCompletion":743,"completion":744,"start":745,"enrollment":746,"conditions":747,"interventions":748},"NCT00414128","Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis",[88,89],"2011-07","2013-02","2007-03",140,[550],[749,729],"mycophenolate mofetil",{"nctId":751,"briefTitle":752,"status":545,"phases":753,"primaryCompletion":754,"start":755,"enrollment":756,"conditions":757,"interventions":760},"NCT01093235","Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer",[89],"2012-04","2009-04",800,[18,758,759],"Cardiac Toxicity","Perioperative\u002FPostoperative Complications",[761,729,762,763,764],"bevacizumab","docetaxel","epirubicin hydrochloride","fluorouracil",{"nctId":766,"briefTitle":767,"status":545,"phases":768,"primaryCompletion":769,"start":770,"enrollment":756,"conditions":771,"interventions":772},"NCT00070278","Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer",[89],"2007-09","2005-01",[18],[729,763,773,774,775,776,777],"gemcitabine hydrochloride","paclitaxel","comparative genomic hybridization","microarray analysis","mutation analysis",{"nctId":779,"briefTitle":780,"status":156,"phases":781,"completion":782,"start":783,"enrollment":784,"conditions":785,"interventions":788},"NCT00430105","Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides",[88,89],"2004-04","1998-02",160,[786,787,29],"ANCA Associated Systemic Vasculitis","Wegener's Granulomatosis",[729],{"trials":790,"activeCount":98},[],{"trials":792,"activeCount":98},[],{"intervention":794,"totalTrials":147,"cells":795},"Rituximab",{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":832,"PHASE4":847,"NA":849},{"trials":797,"activeCount":98},[],{"trials":799,"activeCount":98},[],{"trials":801,"activeCount":98},[802,822],{"nctId":803,"briefTitle":804,"status":499,"phases":805,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":809,"interventions":819},"NCT05168475","Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis",[88],"2023-11-29","2021-07-14",22,[810,811,812,813,814,815,816,817,818],"Giant Cell Arteritis","Takayasu Arteritis","Cogan Syndrome","Relapsing Polychondritis","Cryoglobulinemic Vasculitis","IgA Vasculitis","Polyarteritis Nodosa","Cutaneous Polyarteritis Nodosa","Primary Angiitis of Central Nervous System",[794,820,821],"Infliximab","Tocilizumab",{"nctId":823,"briefTitle":824,"status":156,"phases":825,"completion":826,"start":827,"enrollment":160,"conditions":828,"interventions":831},"NCT00293072","Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis",[88],"2005-05","2002-03",[829,830],"Systemic Lupus Erythematosus","ANCA Associated Vasculitis",[794],{"trials":833,"activeCount":98},[834],{"nctId":835,"briefTitle":836,"status":156,"phases":837,"primaryCompletion":838,"completion":839,"start":840,"enrollment":841,"conditions":842,"interventions":845},"NCT01697267","Rituximab Vasculitis Maintenance Study",[89],"2018-11-22","2019-11-21","2013-04",188,[843,29,844],"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","Wegener Granulomatosis",[794,846],"Azathioprine",{"trials":848,"activeCount":98},[],{"trials":850,"activeCount":98},[],{"intervention":762,"totalTrials":94,"cells":852},{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":881,"NA":883},{"trials":854,"activeCount":98},[],{"trials":856,"activeCount":98},[],{"trials":858,"activeCount":98},[],{"trials":860,"activeCount":98},[861,865],{"nctId":751,"briefTitle":752,"status":545,"phases":862,"primaryCompletion":754,"start":755,"enrollment":756,"conditions":863,"interventions":864},[89],[18,758,759],[761,729,762,763,764],{"nctId":866,"briefTitle":867,"status":156,"phases":868,"primaryCompletion":869,"completion":870,"start":871,"enrollment":872,"conditions":873,"interventions":879},"NCT00978549","Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer",[89],"2010-04","2010-10","2008-04",320,[874,875,876,877,878],"Adenocarcinoma of the Gastroesophageal Junction","Esophageal Cancer","Gastric Cancer","Nausea and Vomiting","Pain",[762,880],"steroid therapy",{"trials":882,"activeCount":98},[],{"trials":884,"activeCount":98},[],{"intervention":763,"totalTrials":94,"cells":886},{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":893,"PHASE4":903,"NA":905},{"trials":888,"activeCount":98},[],{"trials":890,"activeCount":98},[],{"trials":892,"activeCount":98},[],{"trials":894,"activeCount":98},[895,899],{"nctId":751,"briefTitle":752,"status":545,"phases":896,"primaryCompletion":754,"start":755,"enrollment":756,"conditions":897,"interventions":898},[89],[18,758,759],[761,729,762,763,764],{"nctId":766,"briefTitle":767,"status":545,"phases":900,"primaryCompletion":769,"start":770,"enrollment":756,"conditions":901,"interventions":902},[89],[18],[729,763,773,774,775,776,777],{"trials":904,"activeCount":98},[],{"trials":906,"activeCount":98},[],{"intervention":908,"totalTrials":115,"cells":909},"Hydroxychloroquine - Daily dosing",{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":929,"NA":931},{"trials":911,"activeCount":98},[],{"trials":913,"activeCount":98},[],{"trials":915,"activeCount":98},[],{"trials":917,"activeCount":98},[918],{"nctId":919,"briefTitle":920,"status":545,"phases":921,"primaryCompletion":922,"completion":923,"start":924,"enrollment":925,"conditions":926,"interventions":927},"NCT04352933","PROLIFIC ChemoprophylaxisTrial (COVID-19)",[89],"2020-10-31","2021-04","2020-05-11",1000,[27],[908,928],"Hydroxychloroquine - Weekly Dosing",{"trials":930,"activeCount":98},[],{"trials":932,"activeCount":98},[],{"intervention":928,"totalTrials":115,"cells":934},{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":941,"PHASE4":947,"NA":949},{"trials":936,"activeCount":98},[],{"trials":938,"activeCount":98},[],{"trials":940,"activeCount":98},[],{"trials":942,"activeCount":98},[943],{"nctId":919,"briefTitle":920,"status":545,"phases":944,"primaryCompletion":922,"completion":923,"start":924,"enrollment":925,"conditions":945,"interventions":946},[89],[27],[908,928],{"trials":948,"activeCount":98},[],{"trials":950,"activeCount":98},[],{"intervention":952,"totalTrials":115,"cells":953},"Intravenous methyl prednisolone",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":973,"NA":975},{"trials":955,"activeCount":98},[],{"trials":957,"activeCount":98},[],{"trials":959,"activeCount":98},[],{"trials":961,"activeCount":98},[962],{"nctId":963,"briefTitle":964,"status":499,"phases":965,"primaryCompletion":966,"completion":967,"start":968,"enrollment":969,"conditions":970,"interventions":971},"NCT01408836","Plasma Exchange for Renal Vasculitis",[88,89],"2003-06","2003-12","1995-03",150,[787,29],[952,972],"Methyl prednisolone",{"trials":974,"activeCount":98},[],{"trials":976,"activeCount":98},[],{"intervention":972,"totalTrials":115,"cells":978},{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":985,"PHASE4":991,"NA":993},{"trials":980,"activeCount":98},[],{"trials":982,"activeCount":98},[],{"trials":984,"activeCount":98},[],{"trials":986,"activeCount":98},[987],{"nctId":963,"briefTitle":964,"status":499,"phases":988,"primaryCompletion":966,"completion":967,"start":968,"enrollment":969,"conditions":989,"interventions":990},[88,89],[787,29],[952,972],{"trials":992,"activeCount":98},[],{"trials":994,"activeCount":98},[],{"intervention":996,"totalTrials":115,"cells":997},"Apixaban",{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1016,"NA":1018},{"trials":999,"activeCount":98},[],{"trials":1001,"activeCount":98},[],{"trials":1003,"activeCount":98},[],{"trials":1005,"activeCount":98},[1006],{"nctId":1007,"briefTitle":1008,"status":545,"phases":1009,"primaryCompletion":1010,"completion":1010,"start":1011,"enrollment":1012,"conditions":1013,"interventions":1014},"NCT04801940","HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)",[89],"2024-01-31","2021-05-19",2631,[24],[996,1015],"Atorvastatin",{"trials":1017,"activeCount":98},[],{"trials":1019,"activeCount":98},[],{"intervention":1015,"totalTrials":115,"cells":1021},{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1028,"PHASE4":1034,"NA":1036},{"trials":1023,"activeCount":98},[],{"trials":1025,"activeCount":98},[],{"trials":1027,"activeCount":98},[],{"trials":1029,"activeCount":98},[1030],{"nctId":1007,"briefTitle":1008,"status":545,"phases":1031,"primaryCompletion":1010,"completion":1010,"start":1011,"enrollment":1012,"conditions":1032,"interventions":1033},[89],[24],[996,1015],{"trials":1035,"activeCount":98},[],{"trials":1037,"activeCount":98},[],{"intervention":749,"totalTrials":115,"cells":1039},{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1046,"PHASE4":1052,"NA":1054},{"trials":1041,"activeCount":98},[],{"trials":1043,"activeCount":98},[],{"trials":1045,"activeCount":98},[],{"trials":1047,"activeCount":98},[1048],{"nctId":740,"briefTitle":741,"status":156,"phases":1049,"primaryCompletion":743,"completion":744,"start":745,"enrollment":746,"conditions":1050,"interventions":1051},[88,89],[550],[749,729],{"trials":1053,"activeCount":98},[],{"trials":1055,"activeCount":98},[],{"intervention":761,"totalTrials":115,"cells":1057},{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1062,"PHASE3":1064,"PHASE4":1070,"NA":1072},{"trials":1059,"activeCount":98},[],{"trials":1061,"activeCount":98},[],{"trials":1063,"activeCount":98},[],{"trials":1065,"activeCount":98},[1066],{"nctId":751,"briefTitle":752,"status":545,"phases":1067,"primaryCompletion":754,"start":755,"enrollment":756,"conditions":1068,"interventions":1069},[89],[18,758,759],[761,729,762,763,764],{"trials":1071,"activeCount":98},[],{"trials":1073,"activeCount":98},[],{"intervention":764,"totalTrials":115,"cells":1075},{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1082,"PHASE4":1088,"NA":1090},{"trials":1077,"activeCount":98},[],{"trials":1079,"activeCount":98},[],{"trials":1081,"activeCount":98},[],{"trials":1083,"activeCount":98},[1084],{"nctId":751,"briefTitle":752,"status":545,"phases":1085,"primaryCompletion":754,"start":755,"enrollment":756,"conditions":1086,"interventions":1087},[89],[18,758,759],[761,729,762,763,764],{"trials":1089,"activeCount":98},[],{"trials":1091,"activeCount":98},[],{"intervention":846,"totalTrials":115,"cells":1093},{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1100,"PHASE4":1106,"NA":1108},{"trials":1095,"activeCount":98},[],{"trials":1097,"activeCount":98},[],{"trials":1099,"activeCount":98},[],{"trials":1101,"activeCount":98},[1102],{"nctId":835,"briefTitle":836,"status":156,"phases":1103,"primaryCompletion":838,"completion":839,"start":840,"enrollment":841,"conditions":1104,"interventions":1105},[89],[843,29,844],[794,846],{"trials":1107,"activeCount":98},[],{"trials":1109,"activeCount":98},[],{"intervention":773,"totalTrials":115,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1118,"PHASE4":1124,"NA":1126},{"trials":1113,"activeCount":98},[],{"trials":1115,"activeCount":98},[],{"trials":1117,"activeCount":98},[],{"trials":1119,"activeCount":98},[1120],{"nctId":766,"briefTitle":767,"status":545,"phases":1121,"primaryCompletion":769,"start":770,"enrollment":756,"conditions":1122,"interventions":1123},[89],[18],[729,763,773,774,775,776,777],{"trials":1125,"activeCount":98},[],{"trials":1127,"activeCount":98},[],{"intervention":774,"totalTrials":115,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1136,"PHASE4":1142,"NA":1144},{"trials":1131,"activeCount":98},[],{"trials":1133,"activeCount":98},[],{"trials":1135,"activeCount":98},[],{"trials":1137,"activeCount":98},[1138],{"nctId":766,"briefTitle":767,"status":545,"phases":1139,"primaryCompletion":769,"start":770,"enrollment":756,"conditions":1140,"interventions":1141},[89],[18],[729,763,773,774,775,776,777],{"trials":1143,"activeCount":98},[],{"trials":1145,"activeCount":98},[],{"intervention":775,"totalTrials":115,"cells":1147},{"EARLY_PHASE1":1148,"PHASE1":1150,"PHASE2":1152,"PHASE3":1154,"PHASE4":1160,"NA":1162},{"trials":1149,"activeCount":98},[],{"trials":1151,"activeCount":98},[],{"trials":1153,"activeCount":98},[],{"trials":1155,"activeCount":98},[1156],{"nctId":766,"briefTitle":767,"status":545,"phases":1157,"primaryCompletion":769,"start":770,"enrollment":756,"conditions":1158,"interventions":1159},[89],[18],[729,763,773,774,775,776,777],{"trials":1161,"activeCount":98},[],{"trials":1163,"activeCount":98},[],{"intervention":776,"totalTrials":115,"cells":1165},{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1172,"PHASE4":1178,"NA":1180},{"trials":1167,"activeCount":98},[],{"trials":1169,"activeCount":98},[],{"trials":1171,"activeCount":98},[],{"trials":1173,"activeCount":98},[1174],{"nctId":766,"briefTitle":767,"status":545,"phases":1175,"primaryCompletion":769,"start":770,"enrollment":756,"conditions":1176,"interventions":1177},[89],[18],[729,763,773,774,775,776,777],{"trials":1179,"activeCount":98},[],{"trials":1181,"activeCount":98},[],{"intervention":777,"totalTrials":115,"cells":1183},{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1190,"PHASE4":1196,"NA":1198},{"trials":1185,"activeCount":98},[],{"trials":1187,"activeCount":98},[],{"trials":1189,"activeCount":98},[],{"trials":1191,"activeCount":98},[1192],{"nctId":766,"briefTitle":767,"status":545,"phases":1193,"primaryCompletion":769,"start":770,"enrollment":756,"conditions":1194,"interventions":1195},[89],[18],[729,763,773,774,775,776,777],{"trials":1197,"activeCount":98},[],{"trials":1199,"activeCount":98},[],{"intervention":1201,"totalTrials":115,"cells":1202},"EDP1815",{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1223,"NA":1225},{"trials":1204,"activeCount":98},[],{"trials":1206,"activeCount":98},[],{"trials":1208,"activeCount":98},[],{"trials":1210,"activeCount":98},[1211],{"nctId":1212,"briefTitle":1213,"status":156,"phases":1214,"primaryCompletion":1215,"completion":1216,"start":1217,"enrollment":1218,"conditions":1219,"interventions":1220},"NCT04393246","mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms",[88,89],"2022-06-01","2022-06-08","2020-07-03",454,[27],[1201,1221,1222],"Dapagliflozin","Ambrisentan",{"trials":1224,"activeCount":98},[],{"trials":1226,"activeCount":98},[],{"intervention":1221,"totalTrials":115,"cells":1228},{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1233,"PHASE3":1235,"PHASE4":1241,"NA":1243},{"trials":1230,"activeCount":98},[],{"trials":1232,"activeCount":98},[],{"trials":1234,"activeCount":98},[],{"trials":1236,"activeCount":98},[1237],{"nctId":1212,"briefTitle":1213,"status":156,"phases":1238,"primaryCompletion":1215,"completion":1216,"start":1217,"enrollment":1218,"conditions":1239,"interventions":1240},[88,89],[27],[1201,1221,1222],{"trials":1242,"activeCount":98},[],{"trials":1244,"activeCount":98},[],{"intervention":1222,"totalTrials":115,"cells":1246},{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1259,"NA":1261},{"trials":1248,"activeCount":98},[],{"trials":1250,"activeCount":98},[],{"trials":1252,"activeCount":98},[],{"trials":1254,"activeCount":98},[1255],{"nctId":1212,"briefTitle":1213,"status":156,"phases":1256,"primaryCompletion":1215,"completion":1216,"start":1217,"enrollment":1218,"conditions":1257,"interventions":1258},[88,89],[27],[1201,1221,1222],{"trials":1260,"activeCount":98},[],{"trials":1262,"activeCount":98},[],{"intervention":1264,"totalTrials":115,"cells":1265},"prednisolone",{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1272,"PHASE4":1282,"NA":1284},{"trials":1267,"activeCount":98},[],{"trials":1269,"activeCount":98},[],{"trials":1271,"activeCount":98},[],{"trials":1273,"activeCount":98},[1274],{"nctId":1275,"briefTitle":1276,"status":1277,"phases":1278,"enrollment":11,"conditions":1279,"interventions":1281},"NCT00539799","Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis","WITHDRAWN",[89],[1280],"Lupus Nephritis",[1264],{"trials":1283,"activeCount":98},[],{"trials":1285,"activeCount":98},[],{"intervention":880,"totalTrials":115,"cells":1287},{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1292,"PHASE3":1294,"PHASE4":1300,"NA":1302},{"trials":1289,"activeCount":98},[],{"trials":1291,"activeCount":98},[],{"trials":1293,"activeCount":98},[],{"trials":1295,"activeCount":98},[1296],{"nctId":866,"briefTitle":867,"status":156,"phases":1297,"primaryCompletion":869,"completion":870,"start":871,"enrollment":872,"conditions":1298,"interventions":1299},[89],[874,875,876,877,878],[762,880],{"trials":1301,"activeCount":98},[],{"trials":1303,"activeCount":98},[],{"intervention":1305,"totalTrials":115,"cells":1306},"simvastatin",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1313,"PHASE4":1326,"NA":1328},{"trials":1308,"activeCount":98},[],{"trials":1310,"activeCount":98},[],{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":98},[1315],{"nctId":1316,"briefTitle":1317,"status":156,"phases":1318,"primaryCompletion":1319,"completion":1320,"start":1321,"enrollment":1322,"conditions":1323,"interventions":1325},"NCT00731627","Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial",[89],"2013-09","2014-02","2007-01",803,[1324],"Subarachnoid Haemorrhage",[1305],{"trials":1327,"activeCount":98},[],{"trials":1329,"activeCount":98},[],{"intervention":1331,"totalTrials":115,"cells":1332},"Niclosamide",{"EARLY_PHASE1":1333,"PHASE1":1335,"PHASE2":1337,"PHASE3":1339,"PHASE4":1352,"NA":1354},{"trials":1334,"activeCount":98},[],{"trials":1336,"activeCount":98},[],{"trials":1338,"activeCount":98},[],{"trials":1340,"activeCount":98},[1341],{"nctId":1342,"briefTitle":1343,"status":156,"phases":1344,"primaryCompletion":1345,"completion":1345,"start":1346,"enrollment":1347,"conditions":1348,"interventions":1349},"NCT04870333","PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V",[88,89],"2025-04-16","2021-02-19",2240,[24],[1331,1350,1351],"Ciclesonide","Sotrovimab",{"trials":1353,"activeCount":98},[],{"trials":1355,"activeCount":98},[],{"intervention":1350,"totalTrials":115,"cells":1357},{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1364,"PHASE4":1370,"NA":1372},{"trials":1359,"activeCount":98},[],{"trials":1361,"activeCount":98},[],{"trials":1363,"activeCount":98},[],{"trials":1365,"activeCount":98},[1366],{"nctId":1342,"briefTitle":1343,"status":156,"phases":1367,"primaryCompletion":1345,"completion":1345,"start":1346,"enrollment":1347,"conditions":1368,"interventions":1369},[88,89],[24],[1331,1350,1351],{"trials":1371,"activeCount":98},[],{"trials":1373,"activeCount":98},[],{"intervention":1351,"totalTrials":115,"cells":1375},{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1382,"PHASE4":1388,"NA":1390},{"trials":1377,"activeCount":98},[],{"trials":1379,"activeCount":98},[],{"trials":1381,"activeCount":98},[],{"trials":1383,"activeCount":98},[1384],{"nctId":1342,"briefTitle":1343,"status":156,"phases":1385,"primaryCompletion":1345,"completion":1345,"start":1346,"enrollment":1347,"conditions":1386,"interventions":1387},[88,89],[24],[1331,1350,1351],{"trials":1389,"activeCount":98},[],{"trials":1391,"activeCount":98},[],{"intervention":1393,"totalTrials":115,"cells":1394},"Hydroxychloroquine Sulfate 200 MG",{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1399,"PHASE3":1401,"PHASE4":1412,"NA":1414},{"trials":1396,"activeCount":98},[],{"trials":1398,"activeCount":98},[],{"trials":1400,"activeCount":98},[],{"trials":1402,"activeCount":98},[1403],{"nctId":1404,"briefTitle":1405,"status":1277,"phases":1406,"primaryCompletion":1407,"completion":1408,"start":1409,"enrollment":98,"conditions":1410,"interventions":1411},"NCT04389359","PROphylaxis for paTiEnts at Risk of COVID-19 infecTion",[88,89],"2021-08","2025-08","2020-09",[27],[1393],{"trials":1413,"activeCount":98},[],{"trials":1415,"activeCount":98},[],{"intervention":1417,"totalTrials":115,"cells":1418},"Clonidine",{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1425,"PHASE4":1435,"NA":1437},{"trials":1420,"activeCount":98},[],{"trials":1422,"activeCount":98},[],{"trials":1424,"activeCount":98},[],{"trials":1426,"activeCount":98},[1427],{"nctId":1428,"briefTitle":1429,"status":1277,"phases":1430,"completion":479,"start":1431,"enrollment":98,"conditions":1432,"interventions":1434},"NCT00417443","Epidural Clonidine for Postoperative Hyperalgesia",[89],"2007-12",[1433],"Postoperative Hyperalgesia",[1417],{"trials":1436,"activeCount":98},[],{"trials":1438,"activeCount":98},[],{"intervention":486,"totalTrials":94,"cells":1440},{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1445,"PHASE3":1466,"PHASE4":1468,"NA":1470},{"trials":1442,"activeCount":98},[],{"trials":1444,"activeCount":98},[],{"trials":1446,"activeCount":98},[1447,1462],{"nctId":1448,"briefTitle":1449,"status":156,"phases":1450,"primaryCompletion":1451,"completion":1452,"start":1453,"enrollment":160,"conditions":1454,"interventions":1458},"NCT00453232","Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors",[88],"2008-12","2009-01","2004-08",[1455,1456,1457],"Extragonadal Germ Cell Tumor","Teratoma","Testicular Germ Cell Tumor",[1459,1460,486,1461],"bleomycin sulfate","pegfilgrastim","etoposide",{"nctId":476,"briefTitle":477,"status":156,"phases":1463,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":1464,"interventions":1465},[88],[483,484],[467,486,487,488,489,490,491],{"trials":1467,"activeCount":98},[],{"trials":1469,"activeCount":98},[],{"trials":1471,"activeCount":98},[],{"intervention":1459,"totalTrials":115,"cells":1473},{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1478,"PHASE3":1484,"PHASE4":1486,"NA":1488},{"trials":1475,"activeCount":98},[],{"trials":1477,"activeCount":98},[],{"trials":1479,"activeCount":98},[1480],{"nctId":1448,"briefTitle":1449,"status":156,"phases":1481,"primaryCompletion":1451,"completion":1452,"start":1453,"enrollment":160,"conditions":1482,"interventions":1483},[88],[1455,1456,1457],[1459,1460,486,1461],{"trials":1485,"activeCount":98},[],{"trials":1487,"activeCount":98},[],{"trials":1489,"activeCount":98},[],{"intervention":1460,"totalTrials":115,"cells":1491},{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1502,"PHASE4":1504,"NA":1506},{"trials":1493,"activeCount":98},[],{"trials":1495,"activeCount":98},[],{"trials":1497,"activeCount":98},[1498],{"nctId":1448,"briefTitle":1449,"status":156,"phases":1499,"primaryCompletion":1451,"completion":1452,"start":1453,"enrollment":160,"conditions":1500,"interventions":1501},[88],[1455,1456,1457],[1459,1460,486,1461],{"trials":1503,"activeCount":98},[],{"trials":1505,"activeCount":98},[],{"trials":1507,"activeCount":98},[],{"intervention":1461,"totalTrials":115,"cells":1509},{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1520,"PHASE4":1522,"NA":1524},{"trials":1511,"activeCount":98},[],{"trials":1513,"activeCount":98},[],{"trials":1515,"activeCount":98},[1516],{"nctId":1448,"briefTitle":1449,"status":156,"phases":1517,"primaryCompletion":1451,"completion":1452,"start":1453,"enrollment":160,"conditions":1518,"interventions":1519},[88],[1455,1456,1457],[1459,1460,486,1461],{"trials":1521,"activeCount":98},[],{"trials":1523,"activeCount":98},[],{"trials":1525,"activeCount":98},[],{"intervention":1527,"totalTrials":115,"cells":1528},"Pazopanib",{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1554,"PHASE4":1556,"NA":1558},{"trials":1530,"activeCount":98},[],{"trials":1532,"activeCount":98},[],{"trials":1534,"activeCount":98},[1535],{"nctId":1536,"briefTitle":1537,"status":499,"phases":1538,"primaryCompletion":1539,"completion":1540,"start":1541,"enrollment":1542,"conditions":1543,"interventions":1553},"NCT01392352","HYPAZ: Hypertension Induced by Pazopanib",[88],"2014-09","2015-09","2011-04",31,[1544,1545,1546,1547,1548,18,1549,1550,171,1551,1552],"Renal Cell Carcinoma","Soft Tissue Sarcoma","Glioblastoma","Ovarian Cancer","Cervical Cancer","Non-small Cell Lung Cancer","Small Cell Lung Cancer","Melanoma","Gastrointestinal Cancer",[1527],{"trials":1555,"activeCount":98},[],{"trials":1557,"activeCount":98},[],{"trials":1559,"activeCount":98},[],{"intervention":1561,"totalTrials":115,"cells":1562},"GSK1070806",{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1579,"PHASE4":1581,"NA":1583},{"trials":1564,"activeCount":98},[],{"trials":1566,"activeCount":98},[],{"trials":1568,"activeCount":98},[1569],{"nctId":1570,"briefTitle":1571,"status":545,"phases":1572,"primaryCompletion":1573,"completion":1573,"start":1574,"enrollment":1575,"conditions":1576,"interventions":1578},"NCT03522662","Anti IL-18 (GSK1070806) in Behcet's Disease",[88],"2020-04-01","2018-08-01",12,[1577],"Behcet's Disease",[1561],{"trials":1580,"activeCount":98},[],{"trials":1582,"activeCount":98},[],{"trials":1584,"activeCount":98},[],{"intervention":1586,"totalTrials":115,"cells":1587},"vatalanib",{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1589,"activeCount":98},[],{"trials":1591,"activeCount":98},[],{"trials":1593,"activeCount":98},[1594],{"nctId":1595,"briefTitle":1596,"status":156,"phases":1597,"primaryCompletion":1598,"completion":870,"start":1599,"enrollment":1600,"conditions":1601,"interventions":1603},"NCT00563823","Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery",[88],"2008-09","2006-02",34,[1602],"Melanoma (Skin)",[1586],{"trials":1605,"activeCount":98},[],{"trials":1607,"activeCount":98},[],{"trials":1609,"activeCount":98},[],{"intervention":1611,"totalTrials":115,"cells":1612},"Apelin",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1631,"PHASE4":1633,"NA":1635},{"trials":1614,"activeCount":98},[],{"trials":1616,"activeCount":98},[],{"trials":1618,"activeCount":98},[1619],{"nctId":1620,"briefTitle":1621,"status":545,"phases":1622,"primaryCompletion":1623,"completion":1623,"start":1624,"enrollment":1625,"conditions":1626,"interventions":1628},"NCT03449251","A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin",[88],"2025-09","2018-03-28",170,[15,1627],"Type 2 Diabetes Mellitus",[1611,1629,1630],"Relaxin","Normal saline",{"trials":1632,"activeCount":98},[],{"trials":1634,"activeCount":98},[],{"trials":1636,"activeCount":98},[],{"intervention":1629,"totalTrials":115,"cells":1638},{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1643,"PHASE3":1649,"PHASE4":1651,"NA":1653},{"trials":1640,"activeCount":98},[],{"trials":1642,"activeCount":98},[],{"trials":1644,"activeCount":98},[1645],{"nctId":1620,"briefTitle":1621,"status":545,"phases":1646,"primaryCompletion":1623,"completion":1623,"start":1624,"enrollment":1625,"conditions":1647,"interventions":1648},[88],[15,1627],[1611,1629,1630],{"trials":1650,"activeCount":98},[],{"trials":1652,"activeCount":98},[],{"trials":1654,"activeCount":98},[],{"intervention":1630,"totalTrials":115,"cells":1656},{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1667,"PHASE4":1669,"NA":1671},{"trials":1658,"activeCount":98},[],{"trials":1660,"activeCount":98},[],{"trials":1662,"activeCount":98},[1663],{"nctId":1620,"briefTitle":1621,"status":545,"phases":1664,"primaryCompletion":1623,"completion":1623,"start":1624,"enrollment":1625,"conditions":1665,"interventions":1666},[88],[15,1627],[1611,1629,1630],{"trials":1668,"activeCount":98},[],{"trials":1670,"activeCount":98},[],{"trials":1672,"activeCount":98},[],{"intervention":1674,"totalTrials":115,"cells":1675},"Metformin and clemastine in combination",{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1677,"activeCount":98},[],{"trials":1679,"activeCount":98},[],{"trials":1681,"activeCount":98},[1682],{"nctId":1683,"briefTitle":1684,"status":156,"phases":1685,"primaryCompletion":1686,"completion":1687,"start":1688,"enrollment":1689,"conditions":1690,"interventions":1691},"NCT05131828","CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy",[88],"2025-03-31","2025-09-26","2022-03-08",70,[535],[1674],{"trials":1693,"activeCount":98},[],{"trials":1695,"activeCount":98},[],{"trials":1697,"activeCount":98},[],{"intervention":820,"totalTrials":115,"cells":1699},{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1704,"PHASE3":1710,"PHASE4":1712,"NA":1714},{"trials":1701,"activeCount":98},[],{"trials":1703,"activeCount":98},[],{"trials":1705,"activeCount":98},[1706],{"nctId":803,"briefTitle":804,"status":499,"phases":1707,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":1708,"interventions":1709},[88],[810,811,812,813,814,815,816,817,818],[794,820,821],{"trials":1711,"activeCount":98},[],{"trials":1713,"activeCount":98},[],{"trials":1715,"activeCount":98},[],{"intervention":821,"totalTrials":115,"cells":1717},{"EARLY_PHASE1":1718,"PHASE1":1720,"PHASE2":1722,"PHASE3":1728,"PHASE4":1730,"NA":1732},{"trials":1719,"activeCount":98},[],{"trials":1721,"activeCount":98},[],{"trials":1723,"activeCount":98},[1724],{"nctId":803,"briefTitle":804,"status":499,"phases":1725,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":1726,"interventions":1727},[88],[810,811,812,813,814,815,816,817,818],[794,820,821],{"trials":1729,"activeCount":98},[],{"trials":1731,"activeCount":98},[],{"trials":1733,"activeCount":98},[],{"intervention":537,"totalTrials":115,"cells":1735},{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1746,"PHASE4":1748,"NA":1750},{"trials":1737,"activeCount":98},[],{"trials":1739,"activeCount":98},[],{"trials":1741,"activeCount":98},[1742],{"nctId":528,"briefTitle":529,"status":499,"phases":1743,"primaryCompletion":531,"completion":532,"start":533,"enrollment":357,"conditions":1744,"interventions":1745},[87,88],[535],[537,519],{"trials":1747,"activeCount":98},[],{"trials":1749,"activeCount":98},[],{"trials":1751,"activeCount":98},[],{"intervention":1753,"totalTrials":115,"cells":1754},"Megestrol Acetate 40 MG",{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1773,"PHASE4":1775,"NA":1777},{"trials":1756,"activeCount":98},[],{"trials":1758,"activeCount":98},[],{"trials":1760,"activeCount":98},[1761],{"nctId":1762,"briefTitle":1763,"status":156,"phases":1764,"primaryCompletion":1765,"completion":1766,"start":1767,"enrollment":1768,"conditions":1769,"interventions":1770},"NCT03306472","A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer",[88],"2022-10-31","2023-10-31","2017-07-20",198,[18],[1753,1771,1772],"Megestrol Acetate 160 MG","Letrozole",{"trials":1774,"activeCount":98},[],{"trials":1776,"activeCount":98},[],{"trials":1778,"activeCount":98},[],{"intervention":1771,"totalTrials":115,"cells":1780},{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1791,"PHASE4":1793,"NA":1795},{"trials":1782,"activeCount":98},[],{"trials":1784,"activeCount":98},[],{"trials":1786,"activeCount":98},[1787],{"nctId":1762,"briefTitle":1763,"status":156,"phases":1788,"primaryCompletion":1765,"completion":1766,"start":1767,"enrollment":1768,"conditions":1789,"interventions":1790},[88],[18],[1753,1771,1772],{"trials":1792,"activeCount":98},[],{"trials":1794,"activeCount":98},[],{"trials":1796,"activeCount":98},[],{"intervention":1772,"totalTrials":115,"cells":1798},{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1803,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1800,"activeCount":98},[],{"trials":1802,"activeCount":98},[],{"trials":1804,"activeCount":98},[1805],{"nctId":1762,"briefTitle":1763,"status":156,"phases":1806,"primaryCompletion":1765,"completion":1766,"start":1767,"enrollment":1768,"conditions":1807,"interventions":1808},[88],[18],[1753,1771,1772],{"trials":1810,"activeCount":98},[],{"trials":1812,"activeCount":98},[],{"trials":1814,"activeCount":98},[],{"intervention":1816,"totalTrials":115,"cells":1817},"Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination",{"EARLY_PHASE1":1818,"PHASE1":1820,"PHASE2":1822,"PHASE3":1835,"PHASE4":1837,"NA":1839},{"trials":1819,"activeCount":98},[],{"trials":1821,"activeCount":98},[],{"trials":1823,"activeCount":98},[1824],{"nctId":1825,"briefTitle":1826,"status":545,"phases":1827,"primaryCompletion":1828,"completion":1829,"start":1830,"enrollment":1831,"conditions":1832,"interventions":1834},"NCT03514979","Acquired Immunodeficiency in ANCA Associated Vasculitis",[88],"2020-07","2021-01","2018-06",124,[1833],"Systemic Vasculitis",[1816],{"trials":1836,"activeCount":98},[],{"trials":1838,"activeCount":98},[],{"trials":1840,"activeCount":98},[],{"intervention":1842,"totalTrials":115,"cells":1843},"Abatacept",{"EARLY_PHASE1":1844,"PHASE1":1846,"PHASE2":1848,"PHASE3":1860,"PHASE4":1862,"NA":1864},{"trials":1845,"activeCount":98},[],{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":98},[1850],{"nctId":1851,"briefTitle":1852,"status":545,"phases":1853,"primaryCompletion":1854,"completion":1854,"start":1855,"enrollment":8,"conditions":1856,"interventions":1859},"NCT03084419","APRIL (AbatacePt in Rheumatoid Arthritis-ILD)",[88],"2020-03-01","2018-06-26",[1857,1858],"Rheumatoid Arthritis","Interstitial Lung Disease",[1842],{"trials":1861,"activeCount":98},[],{"trials":1863,"activeCount":98},[],{"trials":1865,"activeCount":98},[],{"intervention":1867,"totalTrials":115,"cells":1868},"Proleukin",{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1884,"PHASE4":1886,"NA":1888},{"trials":1870,"activeCount":98},[],{"trials":1872,"activeCount":98},[],{"trials":1874,"activeCount":98},[1875],{"nctId":1876,"briefTitle":1877,"status":156,"phases":1878,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":347,"conditions":1881,"interventions":1883},"NCT03113773","Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes",[87,88],"2019-02-21","2017-05-11",[1882],"Ischemic Heart Disease",[1867],{"trials":1885,"activeCount":98},[],{"trials":1887,"activeCount":98},[],{"trials":1889,"activeCount":98},[],{"intervention":1891,"totalTrials":115,"cells":1892},"Dabrafenib",{"EARLY_PHASE1":1893,"PHASE1":1895,"PHASE2":1897,"PHASE3":1910,"PHASE4":1912,"NA":1914},{"trials":1894,"activeCount":98},[],{"trials":1896,"activeCount":98},[],{"trials":1898,"activeCount":98},[1899],{"nctId":1900,"briefTitle":1901,"status":156,"phases":1902,"primaryCompletion":1903,"completion":1904,"start":1905,"enrollment":1906,"conditions":1907,"interventions":1908},"NCT03352947","Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma",[88],"2020-03-31","2020-11-27","2017-11-03",79,[1551],[1891,1909],"Trametinib",{"trials":1911,"activeCount":98},[],{"trials":1913,"activeCount":98},[],{"trials":1915,"activeCount":98},[],{"intervention":1909,"totalTrials":115,"cells":1917},{"EARLY_PHASE1":1918,"PHASE1":1920,"PHASE2":1922,"PHASE3":1928,"PHASE4":1930,"NA":1932},{"trials":1919,"activeCount":98},[],{"trials":1921,"activeCount":98},[],{"trials":1923,"activeCount":98},[1924],{"nctId":1900,"briefTitle":1901,"status":156,"phases":1925,"primaryCompletion":1903,"completion":1904,"start":1905,"enrollment":1906,"conditions":1926,"interventions":1927},[88],[1551],[1891,1909],{"trials":1929,"activeCount":98},[],{"trials":1931,"activeCount":98},[],{"trials":1933,"activeCount":98},[],{"intervention":487,"totalTrials":115,"cells":1935},{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1940,"PHASE3":1946,"PHASE4":1948,"NA":1950},{"trials":1937,"activeCount":98},[],{"trials":1939,"activeCount":98},[],{"trials":1941,"activeCount":98},[1942],{"nctId":476,"briefTitle":477,"status":156,"phases":1943,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":1944,"interventions":1945},[88],[483,484],[467,486,487,488,489,490,491],{"trials":1947,"activeCount":98},[],{"trials":1949,"activeCount":98},[],{"trials":1951,"activeCount":98},[],{"intervention":488,"totalTrials":115,"cells":1953},{"EARLY_PHASE1":1954,"PHASE1":1956,"PHASE2":1958,"PHASE3":1964,"PHASE4":1966,"NA":1968},{"trials":1955,"activeCount":98},[],{"trials":1957,"activeCount":98},[],{"trials":1959,"activeCount":98},[1960],{"nctId":476,"briefTitle":477,"status":156,"phases":1961,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":1962,"interventions":1963},[88],[483,484],[467,486,487,488,489,490,491],{"trials":1965,"activeCount":98},[],{"trials":1967,"activeCount":98},[],{"trials":1969,"activeCount":98},[],{"intervention":489,"totalTrials":115,"cells":1971},{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1976,"PHASE3":1982,"PHASE4":1984,"NA":1986},{"trials":1973,"activeCount":98},[],{"trials":1975,"activeCount":98},[],{"trials":1977,"activeCount":98},[1978],{"nctId":476,"briefTitle":477,"status":156,"phases":1979,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":1980,"interventions":1981},[88],[483,484],[467,486,487,488,489,490,491],{"trials":1983,"activeCount":98},[],{"trials":1985,"activeCount":98},[],{"trials":1987,"activeCount":98},[],{"intervention":490,"totalTrials":115,"cells":1989},{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":2000,"PHASE4":2002,"NA":2004},{"trials":1991,"activeCount":98},[],{"trials":1993,"activeCount":98},[],{"trials":1995,"activeCount":98},[1996],{"nctId":476,"briefTitle":477,"status":156,"phases":1997,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":1998,"interventions":1999},[88],[483,484],[467,486,487,488,489,490,491],{"trials":2001,"activeCount":98},[],{"trials":2003,"activeCount":98},[],{"trials":2005,"activeCount":98},[],{"intervention":491,"totalTrials":115,"cells":2007},{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2018,"PHASE4":2020,"NA":2022},{"trials":2009,"activeCount":98},[],{"trials":2011,"activeCount":98},[],{"trials":2013,"activeCount":98},[2014],{"nctId":476,"briefTitle":477,"status":156,"phases":2015,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":2016,"interventions":2017},[88],[483,484],[467,486,487,488,489,490,491],{"trials":2019,"activeCount":98},[],{"trials":2021,"activeCount":98},[],{"trials":2023,"activeCount":98},[],{"intervention":2025,"totalTrials":115,"cells":2026},"Afatinib",{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2047,"PHASE4":2049,"NA":2051},{"trials":2028,"activeCount":98},[],{"trials":2030,"activeCount":98},[],{"trials":2032,"activeCount":98},[2033],{"nctId":2034,"briefTitle":2035,"status":499,"phases":2036,"primaryCompletion":2037,"completion":2038,"start":2039,"enrollment":2040,"conditions":2041,"interventions":2046},"NCT02768337","Cambridge Brain Mets Trial 1",[87,88],"2020-08-12","2021-08-12","2015-03-10",26,[2042,18,2043,2044,2045],"Lung Cancer","Brain Cancer","Advanced Breast Cancer","Advanced Lung Cancer",[2025],{"trials":2048,"activeCount":98},[],{"trials":2050,"activeCount":98},[],{"trials":2052,"activeCount":98},[],{"intervention":2054,"totalTrials":115,"cells":2055},"Losmapimod",{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2070,"PHASE4":2072,"NA":2074},{"trials":2057,"activeCount":98},[],{"trials":2059,"activeCount":98},[],{"trials":2061,"activeCount":98},[2062],{"nctId":2063,"briefTitle":2064,"status":156,"phases":2065,"primaryCompletion":1320,"completion":1320,"start":533,"enrollment":2066,"conditions":2067,"interventions":2069},"NCT01541852","Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.",[88],72,[2068],"Chronic Obstructive Pulmonary Disease",[2054],{"trials":2071,"activeCount":98},[],{"trials":2073,"activeCount":98},[],{"trials":2075,"activeCount":98},[],{"intervention":2077,"totalTrials":115,"cells":2078},"Albuterol Sulfate",{"EARLY_PHASE1":2079,"PHASE1":2081,"PHASE2":2099,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2080,"activeCount":98},[],{"trials":2082,"activeCount":98},[2083],{"nctId":2084,"briefTitle":2085,"status":499,"phases":2086,"primaryCompletion":2087,"completion":2087,"start":2088,"enrollment":2089,"conditions":2090,"interventions":2093},"NCT03098680","A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems",[87],"2020-02-29","2017-04-24",18,[2091,2092],"Drug-Related Side Effects and Adverse Reactions","Cardiovascular System Disease",[2077,2094,2095,2096,2097,2098],"Nicardipine Hydrochloride","Dobutamine Hydrochloride","Phenylephrine Hydrochloride","Verapamil Hydrochloride","Phentolamine Mesylate",{"trials":2100,"activeCount":98},[],{"trials":2102,"activeCount":98},[],{"trials":2104,"activeCount":98},[],{"trials":2106,"activeCount":98},[],{"intervention":2094,"totalTrials":115,"cells":2108},{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2117,"PHASE3":2119,"PHASE4":2121,"NA":2123},{"trials":2110,"activeCount":98},[],{"trials":2112,"activeCount":98},[2113],{"nctId":2084,"briefTitle":2085,"status":499,"phases":2114,"primaryCompletion":2087,"completion":2087,"start":2088,"enrollment":2089,"conditions":2115,"interventions":2116},[87],[2091,2092],[2077,2094,2095,2096,2097,2098],{"trials":2118,"activeCount":98},[],{"trials":2120,"activeCount":98},[],{"trials":2122,"activeCount":98},[],{"trials":2124,"activeCount":98},[],{"intervention":2095,"totalTrials":115,"cells":2126},{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2135,"PHASE3":2137,"PHASE4":2139,"NA":2141},{"trials":2128,"activeCount":98},[],{"trials":2130,"activeCount":98},[2131],{"nctId":2084,"briefTitle":2085,"status":499,"phases":2132,"primaryCompletion":2087,"completion":2087,"start":2088,"enrollment":2089,"conditions":2133,"interventions":2134},[87],[2091,2092],[2077,2094,2095,2096,2097,2098],{"trials":2136,"activeCount":98},[],{"trials":2138,"activeCount":98},[],{"trials":2140,"activeCount":98},[],{"trials":2142,"activeCount":98},[],{"intervention":2096,"totalTrials":115,"cells":2144},{"EARLY_PHASE1":2145,"PHASE1":2147,"PHASE2":2153,"PHASE3":2155,"PHASE4":2157,"NA":2159},{"trials":2146,"activeCount":98},[],{"trials":2148,"activeCount":98},[2149],{"nctId":2084,"briefTitle":2085,"status":499,"phases":2150,"primaryCompletion":2087,"completion":2087,"start":2088,"enrollment":2089,"conditions":2151,"interventions":2152},[87],[2091,2092],[2077,2094,2095,2096,2097,2098],{"trials":2154,"activeCount":98},[],{"trials":2156,"activeCount":98},[],{"trials":2158,"activeCount":98},[],{"trials":2160,"activeCount":98},[],{"intervention":2097,"totalTrials":115,"cells":2162},{"EARLY_PHASE1":2163,"PHASE1":2165,"PHASE2":2171,"PHASE3":2173,"PHASE4":2175,"NA":2177},{"trials":2164,"activeCount":98},[],{"trials":2166,"activeCount":98},[2167],{"nctId":2084,"briefTitle":2085,"status":499,"phases":2168,"primaryCompletion":2087,"completion":2087,"start":2088,"enrollment":2089,"conditions":2169,"interventions":2170},[87],[2091,2092],[2077,2094,2095,2096,2097,2098],{"trials":2172,"activeCount":98},[],{"trials":2174,"activeCount":98},[],{"trials":2176,"activeCount":98},[],{"trials":2178,"activeCount":98},[],{"intervention":2098,"totalTrials":115,"cells":2180},{"EARLY_PHASE1":2181,"PHASE1":2183,"PHASE2":2189,"PHASE3":2191,"PHASE4":2193,"NA":2195},{"trials":2182,"activeCount":98},[],{"trials":2184,"activeCount":98},[2185],{"nctId":2084,"briefTitle":2085,"status":499,"phases":2186,"primaryCompletion":2087,"completion":2087,"start":2088,"enrollment":2089,"conditions":2187,"interventions":2188},[87],[2091,2092],[2077,2094,2095,2096,2097,2098],{"trials":2190,"activeCount":98},[],{"trials":2192,"activeCount":98},[],{"trials":2194,"activeCount":98},[],{"trials":2196,"activeCount":98},[],{"intervention":2198,"totalTrials":115,"cells":2199},"AZD2014",{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2211,"PHASE3":2213,"PHASE4":2215,"NA":2217},{"trials":2201,"activeCount":98},[],{"trials":2203,"activeCount":98},[2204],{"nctId":2205,"briefTitle":2206,"status":156,"phases":2207,"primaryCompletion":159,"completion":1830,"start":502,"enrollment":2208,"conditions":2209,"interventions":2210},"NCT02064608","Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer",[87],23,[21],[2198],{"trials":2212,"activeCount":98},[],{"trials":2214,"activeCount":98},[],{"trials":2216,"activeCount":98},[],{"trials":2218,"activeCount":98},[],{"intervention":163,"totalTrials":115,"cells":2220},{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2229,"PHASE3":2231,"PHASE4":2233,"NA":2235},{"trials":2222,"activeCount":98},[],{"trials":2224,"activeCount":98},[2225],{"nctId":154,"briefTitle":155,"status":156,"phases":2226,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":2227,"interventions":2228},[87],[21],[39,163],{"trials":2230,"activeCount":98},[],{"trials":2232,"activeCount":98},[],{"trials":2234,"activeCount":98},[],{"trials":2236,"activeCount":98},[],{"intervention":2238,"totalTrials":115,"cells":2239},"Sumatriptan 100 mg",{"EARLY_PHASE1":2240,"PHASE1":2251,"PHASE2":2253,"PHASE3":2255,"PHASE4":2257,"NA":2259},{"trials":2241,"activeCount":98},[2242],{"nctId":2243,"briefTitle":2244,"status":545,"phases":2245,"primaryCompletion":2246,"completion":2246,"start":2247,"enrollment":1575,"conditions":2248,"interventions":2250},"NCT04690270","Sumatriptan and Glucose",[86],"2021-06-25","2021-01-04",[2249],"Overweight",[2238],{"trials":2252,"activeCount":98},[],{"trials":2254,"activeCount":98},[],{"trials":2256,"activeCount":98},[],{"trials":2258,"activeCount":98},[],{"trials":2260,"activeCount":98},[],{"intervention":578,"totalTrials":94,"cells":2262},{"EARLY_PHASE1":2263,"PHASE1":2265,"PHASE2":2267,"PHASE3":2269,"PHASE4":2271,"NA":2277},{"trials":2264,"activeCount":98},[],{"trials":2266,"activeCount":98},[],{"trials":2268,"activeCount":98},[],{"trials":2270,"activeCount":98},[],{"trials":2272,"activeCount":98},[2273],{"nctId":570,"briefTitle":571,"status":156,"phases":2274,"primaryCompletion":573,"completion":573,"start":574,"enrollment":575,"conditions":2275,"interventions":2276},[90],[31],[578,557,579,580],{"trials":2278,"activeCount":98},[2279],{"nctId":2280,"briefTitle":2281,"status":545,"phases":2282,"primaryCompletion":2283,"completion":2283,"start":2284,"enrollment":123,"conditions":2285,"interventions":2286},"NCT05976438","Skin Sodium and Salt Sensitivity of Blood Pressure",[91],"2024-12","2023-08",[31],[578,580],{"intervention":580,"totalTrials":94,"cells":2288},{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2293,"PHASE3":2295,"PHASE4":2297,"NA":2303},{"trials":2290,"activeCount":98},[],{"trials":2292,"activeCount":98},[],{"trials":2294,"activeCount":98},[],{"trials":2296,"activeCount":98},[],{"trials":2298,"activeCount":98},[2299],{"nctId":570,"briefTitle":571,"status":156,"phases":2300,"primaryCompletion":573,"completion":573,"start":574,"enrollment":575,"conditions":2301,"interventions":2302},[90],[31],[578,557,579,580],{"trials":2304,"activeCount":98},[2305],{"nctId":2280,"briefTitle":2281,"status":545,"phases":2306,"primaryCompletion":2283,"completion":2283,"start":2284,"enrollment":123,"conditions":2307,"interventions":2308},[91],[31],[578,580],{"intervention":2310,"totalTrials":115,"cells":2311},"Dosing",{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2316,"PHASE3":2318,"PHASE4":2320,"NA":2322},{"trials":2313,"activeCount":98},[],{"trials":2315,"activeCount":98},[],{"trials":2317,"activeCount":98},[],{"trials":2319,"activeCount":98},[],{"trials":2321,"activeCount":98},[],{"trials":2323,"activeCount":98},[2324],{"nctId":2325,"briefTitle":2326,"status":156,"phases":2327,"primaryCompletion":2328,"completion":2328,"start":2329,"enrollment":8,"conditions":2330,"interventions":2332},"NCT03273972","INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers",[91],"2018-10-10","2017-09-07",[2331,15],"Atherosclerosis",[2310],{"intervention":2334,"totalTrials":115,"cells":2335},"Organoid in vitro culture",{"EARLY_PHASE1":2336,"PHASE1":2338,"PHASE2":2340,"PHASE3":2342,"PHASE4":2344,"NA":2346},{"trials":2337,"activeCount":98},[],{"trials":2339,"activeCount":98},[],{"trials":2341,"activeCount":98},[],{"trials":2343,"activeCount":98},[],{"trials":2345,"activeCount":98},[],{"trials":2347,"activeCount":98},[2348],{"nctId":2349,"briefTitle":2350,"status":545,"phases":2351,"primaryCompletion":2352,"start":2353,"enrollment":2354,"conditions":2355,"interventions":2359},"NCT02436564","In Vitro Models of Liver and Pancreatic Cancer",[],"2018-09","2015-07",75,[2356,2357,2358],"Cholangiocarcinoma","Hepatocellular Carcinoma","Pancreatic Neoplasm",[2334],{"intervention":2361,"totalTrials":115,"cells":2362},"Darbepoetin Alfa",{"EARLY_PHASE1":2363,"PHASE1":2365,"PHASE2":2367,"PHASE3":2369,"PHASE4":2371,"NA":2373},{"trials":2364,"activeCount":98},[],{"trials":2366,"activeCount":98},[],{"trials":2368,"activeCount":98},[],{"trials":2370,"activeCount":98},[],{"trials":2372,"activeCount":98},[],{"trials":2374,"activeCount":98},[2375],{"nctId":2376,"briefTitle":2377,"status":156,"phases":2378,"primaryCompletion":2379,"completion":2379,"start":2380,"enrollment":2381,"conditions":2382,"interventions":2384},"NCT02987465","Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.",[],"2018-05-21","2017-02-20",29,[15,2383],"Chronic Kidney Disease",[2361,2385,2386,2387],"Acetylcholine","Noradrenaline","BQ 123",{"intervention":2385,"totalTrials":115,"cells":2389},{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2394,"PHASE3":2396,"PHASE4":2398,"NA":2400},{"trials":2391,"activeCount":98},[],{"trials":2393,"activeCount":98},[],{"trials":2395,"activeCount":98},[],{"trials":2397,"activeCount":98},[],{"trials":2399,"activeCount":98},[],{"trials":2401,"activeCount":98},[2402],{"nctId":2376,"briefTitle":2377,"status":156,"phases":2403,"primaryCompletion":2379,"completion":2379,"start":2380,"enrollment":2381,"conditions":2404,"interventions":2405},[],[15,2383],[2361,2385,2386,2387],{"intervention":2386,"totalTrials":115,"cells":2407},{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2414,"PHASE4":2416,"NA":2418},{"trials":2409,"activeCount":98},[],{"trials":2411,"activeCount":98},[],{"trials":2413,"activeCount":98},[],{"trials":2415,"activeCount":98},[],{"trials":2417,"activeCount":98},[],{"trials":2419,"activeCount":98},[2420],{"nctId":2376,"briefTitle":2377,"status":156,"phases":2421,"primaryCompletion":2379,"completion":2379,"start":2380,"enrollment":2381,"conditions":2422,"interventions":2423},[],[15,2383],[2361,2385,2386,2387],{"intervention":2387,"totalTrials":115,"cells":2425},{"EARLY_PHASE1":2426,"PHASE1":2428,"PHASE2":2430,"PHASE3":2432,"PHASE4":2434,"NA":2436},{"trials":2427,"activeCount":98},[],{"trials":2429,"activeCount":98},[],{"trials":2431,"activeCount":98},[],{"trials":2433,"activeCount":98},[],{"trials":2435,"activeCount":98},[],{"trials":2437,"activeCount":98},[2438],{"nctId":2376,"briefTitle":2377,"status":156,"phases":2439,"primaryCompletion":2379,"completion":2379,"start":2380,"enrollment":2381,"conditions":2440,"interventions":2441},[],[15,2383],[2361,2385,2386,2387],{"intervention":2443,"totalTrials":115,"cells":2444},"Metformin",{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2446,"activeCount":98},[],{"trials":2448,"activeCount":98},[],{"trials":2450,"activeCount":98},[],{"trials":2452,"activeCount":98},[],{"trials":2454,"activeCount":98},[],{"trials":2456,"activeCount":98},[2457],{"nctId":2458,"briefTitle":2459,"status":545,"phases":2460,"primaryCompletion":2461,"completion":2462,"start":574,"enrollment":460,"conditions":2463,"interventions":2465},"NCT02931591","Effect of Insulin Sensitization on IGF-1 Response to Growth Hormone in SGA Children",[91],"2019-11","2020-06",[2464],"Small for Gestational Age",[2443,2466],"Growth Hormone",{"intervention":2466,"totalTrials":115,"cells":2468},{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2473,"PHASE3":2475,"PHASE4":2477,"NA":2479},{"trials":2470,"activeCount":98},[],{"trials":2472,"activeCount":98},[],{"trials":2474,"activeCount":98},[],{"trials":2476,"activeCount":98},[],{"trials":2478,"activeCount":98},[],{"trials":2480,"activeCount":98},[2481],{"nctId":2458,"briefTitle":2459,"status":545,"phases":2482,"primaryCompletion":2461,"completion":2462,"start":574,"enrollment":460,"conditions":2483,"interventions":2484},[91],[2464],[2443,2466],{"intervention":2486,"totalTrials":115,"cells":2487},"Modafinil",{"EARLY_PHASE1":2488,"PHASE1":2490,"PHASE2":2492,"PHASE3":2494,"PHASE4":2496,"NA":2498},{"trials":2489,"activeCount":98},[],{"trials":2491,"activeCount":98},[],{"trials":2493,"activeCount":98},[],{"trials":2495,"activeCount":98},[],{"trials":2497,"activeCount":98},[],{"trials":2499,"activeCount":98},[2500],{"nctId":2501,"briefTitle":2502,"status":156,"phases":2503,"primaryCompletion":2504,"completion":2505,"start":2506,"enrollment":2507,"conditions":2508,"interventions":2515},"NCT02051153","Neurochemical Modulation Cognitive Performance and Subjective Wellbeing In Healthy Controls",[91],"2011-08","2011-09","2009-10",64,[2509,2510,2511,2512,2513,2514],"Cognitive Performance","Creativity","Motivation","Reward","Healthy Volunteers","Subjective Pleasure",[2486],{"intervention":2517,"totalTrials":115,"cells":2518},"Alirocumab 150 MG\u002FML",{"EARLY_PHASE1":2519,"PHASE1":2521,"PHASE2":2523,"PHASE3":2525,"PHASE4":2527,"NA":2529},{"trials":2520,"activeCount":98},[],{"trials":2522,"activeCount":98},[],{"trials":2524,"activeCount":98},[],{"trials":2526,"activeCount":98},[],{"trials":2528,"activeCount":98},[],{"trials":2530,"activeCount":98},[2531],{"nctId":2532,"briefTitle":2533,"status":545,"phases":2534,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":123,"conditions":2538,"interventions":2539},"NCT03355027","Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease",[91],"2019-09-30","2023-11-30","2017-11-30",[2331,15],[2517,2540,2541,2542,2543,2544,2545],"Ezetimibe 10Mg","Atorvastatin 40Mg","Atorvastatin 80Mg","Rosuvastatin 20Mg","Rosuvastatin 40Mg","Simvastatin 80mg",{"intervention":2540,"totalTrials":115,"cells":2547},{"EARLY_PHASE1":2548,"PHASE1":2550,"PHASE2":2552,"PHASE3":2554,"PHASE4":2556,"NA":2558},{"trials":2549,"activeCount":98},[],{"trials":2551,"activeCount":98},[],{"trials":2553,"activeCount":98},[],{"trials":2555,"activeCount":98},[],{"trials":2557,"activeCount":98},[],{"trials":2559,"activeCount":98},[2560],{"nctId":2532,"briefTitle":2533,"status":545,"phases":2561,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":123,"conditions":2562,"interventions":2563},[91],[2331,15],[2517,2540,2541,2542,2543,2544,2545],{"intervention":2541,"totalTrials":115,"cells":2565},{"EARLY_PHASE1":2566,"PHASE1":2568,"PHASE2":2570,"PHASE3":2572,"PHASE4":2574,"NA":2576},{"trials":2567,"activeCount":98},[],{"trials":2569,"activeCount":98},[],{"trials":2571,"activeCount":98},[],{"trials":2573,"activeCount":98},[],{"trials":2575,"activeCount":98},[],{"trials":2577,"activeCount":98},[2578],{"nctId":2532,"briefTitle":2533,"status":545,"phases":2579,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":123,"conditions":2580,"interventions":2581},[91],[2331,15],[2517,2540,2541,2542,2543,2544,2545],{"intervention":2542,"totalTrials":115,"cells":2583},{"EARLY_PHASE1":2584,"PHASE1":2586,"PHASE2":2588,"PHASE3":2590,"PHASE4":2592,"NA":2594},{"trials":2585,"activeCount":98},[],{"trials":2587,"activeCount":98},[],{"trials":2589,"activeCount":98},[],{"trials":2591,"activeCount":98},[],{"trials":2593,"activeCount":98},[],{"trials":2595,"activeCount":98},[2596],{"nctId":2532,"briefTitle":2533,"status":545,"phases":2597,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":123,"conditions":2598,"interventions":2599},[91],[2331,15],[2517,2540,2541,2542,2543,2544,2545],{"intervention":2543,"totalTrials":115,"cells":2601},{"EARLY_PHASE1":2602,"PHASE1":2604,"PHASE2":2606,"PHASE3":2608,"PHASE4":2610,"NA":2612},{"trials":2603,"activeCount":98},[],{"trials":2605,"activeCount":98},[],{"trials":2607,"activeCount":98},[],{"trials":2609,"activeCount":98},[],{"trials":2611,"activeCount":98},[],{"trials":2613,"activeCount":98},[2614],{"nctId":2532,"briefTitle":2533,"status":545,"phases":2615,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":123,"conditions":2616,"interventions":2617},[91],[2331,15],[2517,2540,2541,2542,2543,2544,2545],{"intervention":2544,"totalTrials":115,"cells":2619},{"EARLY_PHASE1":2620,"PHASE1":2622,"PHASE2":2624,"PHASE3":2626,"PHASE4":2628,"NA":2630},{"trials":2621,"activeCount":98},[],{"trials":2623,"activeCount":98},[],{"trials":2625,"activeCount":98},[],{"trials":2627,"activeCount":98},[],{"trials":2629,"activeCount":98},[],{"trials":2631,"activeCount":98},[2632],{"nctId":2532,"briefTitle":2533,"status":545,"phases":2633,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":123,"conditions":2634,"interventions":2635},[91],[2331,15],[2517,2540,2541,2542,2543,2544,2545],{"intervention":2545,"totalTrials":115,"cells":2637},{"EARLY_PHASE1":2638,"PHASE1":2640,"PHASE2":2642,"PHASE3":2644,"PHASE4":2646,"NA":2648},{"trials":2639,"activeCount":98},[],{"trials":2641,"activeCount":98},[],{"trials":2643,"activeCount":98},[],{"trials":2645,"activeCount":98},[],{"trials":2647,"activeCount":98},[],{"trials":2649,"activeCount":98},[2650],{"nctId":2532,"briefTitle":2533,"status":545,"phases":2651,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":123,"conditions":2652,"interventions":2653},[91],[2331,15],[2517,2540,2541,2542,2543,2544,2545],{"intervention":2655,"totalTrials":115,"cells":2656},"Somatostatin",{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2661,"PHASE3":2663,"PHASE4":2665,"NA":2667},{"trials":2658,"activeCount":98},[],{"trials":2660,"activeCount":98},[],{"trials":2662,"activeCount":98},[],{"trials":2664,"activeCount":98},[],{"trials":2666,"activeCount":98},[],{"trials":2668,"activeCount":98},[2669],{"nctId":2670,"briefTitle":2671,"status":499,"phases":2672,"primaryCompletion":2673,"completion":2673,"start":2674,"enrollment":2675,"conditions":2676,"interventions":2681},"NCT02836353","Metabolic Consequences of Gastrointestinal Surgery",[91],"2019-03-11","2017-01",81,[2677,2678,2679,2680],"Gastrectomy","Oesophagectomy","Dumping Syndrome","Hypoglycaemia",[2655,2682],"Rifaximin",{"intervention":2682,"totalTrials":115,"cells":2684},{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2689,"PHASE3":2691,"PHASE4":2693,"NA":2695},{"trials":2686,"activeCount":98},[],{"trials":2688,"activeCount":98},[],{"trials":2690,"activeCount":98},[],{"trials":2692,"activeCount":98},[],{"trials":2694,"activeCount":98},[],{"trials":2696,"activeCount":98},[2697],{"nctId":2670,"briefTitle":2671,"status":499,"phases":2698,"primaryCompletion":2673,"completion":2673,"start":2674,"enrollment":2675,"conditions":2699,"interventions":2700},[91],[2677,2678,2679,2680],[2655,2682],{"intervention":2702,"totalTrials":115,"cells":2703},"Saline 0.9%",{"EARLY_PHASE1":2704,"PHASE1":2706,"PHASE2":2708,"PHASE3":2710,"PHASE4":2712,"NA":2714},{"trials":2705,"activeCount":98},[],{"trials":2707,"activeCount":98},[],{"trials":2709,"activeCount":98},[],{"trials":2711,"activeCount":98},[],{"trials":2713,"activeCount":98},[],{"trials":2715,"activeCount":98},[2716],{"nctId":2717,"briefTitle":2718,"status":156,"phases":2719,"primaryCompletion":2720,"completion":2720,"start":2721,"enrollment":2040,"conditions":2722,"interventions":2723},"NCT03835013","Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers",[91],"2021-11-01","2019-02-11",[15],[2702,2724,2724,2725],"Glucagon","Exenatide",{"intervention":2724,"totalTrials":115,"cells":2727},{"EARLY_PHASE1":2728,"PHASE1":2730,"PHASE2":2732,"PHASE3":2734,"PHASE4":2736,"NA":2738},{"trials":2729,"activeCount":98},[],{"trials":2731,"activeCount":98},[],{"trials":2733,"activeCount":98},[],{"trials":2735,"activeCount":98},[],{"trials":2737,"activeCount":98},[],{"trials":2739,"activeCount":98},[2740],{"nctId":2717,"briefTitle":2718,"status":156,"phases":2741,"primaryCompletion":2720,"completion":2720,"start":2721,"enrollment":2040,"conditions":2742,"interventions":2743},[91],[15],[2702,2724,2724,2725],{"intervention":2725,"totalTrials":115,"cells":2745},{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2750,"PHASE3":2752,"PHASE4":2754,"NA":2756},{"trials":2747,"activeCount":98},[],{"trials":2749,"activeCount":98},[],{"trials":2751,"activeCount":98},[],{"trials":2753,"activeCount":98},[],{"trials":2755,"activeCount":98},[],{"trials":2757,"activeCount":98},[2758],{"nctId":2717,"briefTitle":2718,"status":156,"phases":2759,"primaryCompletion":2720,"completion":2720,"start":2721,"enrollment":2040,"conditions":2760,"interventions":2761},[91],[15],[2702,2724,2724,2725],{"intervention":2763,"totalTrials":115,"cells":2764},"Anacetrapib",{"EARLY_PHASE1":2765,"PHASE1":2767,"PHASE2":2769,"PHASE3":2771,"PHASE4":2773,"NA":2775},{"trials":2766,"activeCount":98},[],{"trials":2768,"activeCount":98},[],{"trials":2770,"activeCount":98},[],{"trials":2772,"activeCount":98},[],{"trials":2774,"activeCount":98},[],{"trials":2776,"activeCount":98},[2777],{"nctId":2778,"briefTitle":2779,"status":156,"phases":2780,"primaryCompletion":2781,"completion":2781,"start":2674,"enrollment":2782,"conditions":2783,"interventions":2786},"NCT02931188","The Effect of Anacetrapib on Vascular Function and Arterial Stiffness",[],"2018-05",103,[2784,2785],"Atherosclerotic Cardiovascular Disease","Vascular Disease",[2763,2787],"Statin",{"intervention":2787,"totalTrials":115,"cells":2789},{"EARLY_PHASE1":2790,"PHASE1":2792,"PHASE2":2794,"PHASE3":2796,"PHASE4":2798,"NA":2800},{"trials":2791,"activeCount":98},[],{"trials":2793,"activeCount":98},[],{"trials":2795,"activeCount":98},[],{"trials":2797,"activeCount":98},[],{"trials":2799,"activeCount":98},[],{"trials":2801,"activeCount":98},[2802],{"nctId":2778,"briefTitle":2779,"status":156,"phases":2803,"primaryCompletion":2781,"completion":2781,"start":2674,"enrollment":2782,"conditions":2804,"interventions":2805},[],[2784,2785],[2763,2787],{"intervention":2807,"totalTrials":115,"cells":2808},"R848",{"EARLY_PHASE1":2809,"PHASE1":2811,"PHASE2":2813,"PHASE3":2815,"PHASE4":2817,"NA":2819},{"trials":2810,"activeCount":98},[],{"trials":2812,"activeCount":98},[],{"trials":2814,"activeCount":98},[],{"trials":2816,"activeCount":98},[],{"trials":2818,"activeCount":98},[],{"trials":2820,"activeCount":98},[2821],{"nctId":2822,"briefTitle":2823,"status":545,"phases":2824,"primaryCompletion":2825,"completion":2825,"start":2826,"enrollment":460,"conditions":2827,"interventions":2831},"NCT06021002","Nasal Immune Challenge Study",[91],"2024-09-30","2022-08-09",[2828,2829,2830],"Innate Inflammatory Response","Asthma","Nasal Allergy",[2807,2832],"Saline",{"intervention":2832,"totalTrials":115,"cells":2834},{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2839,"PHASE3":2841,"PHASE4":2843,"NA":2845},{"trials":2836,"activeCount":98},[],{"trials":2838,"activeCount":98},[],{"trials":2840,"activeCount":98},[],{"trials":2842,"activeCount":98},[],{"trials":2844,"activeCount":98},[],{"trials":2846,"activeCount":98},[2847],{"nctId":2822,"briefTitle":2823,"status":545,"phases":2848,"primaryCompletion":2825,"completion":2825,"start":2826,"enrollment":460,"conditions":2849,"interventions":2850},[91],[2828,2829,2830],[2807,2832],{"intervention":2852,"totalTrials":115,"cells":2853},"Levobupivacaine",{"EARLY_PHASE1":2854,"PHASE1":2856,"PHASE2":2858,"PHASE3":2860,"PHASE4":2862,"NA":2864},{"trials":2855,"activeCount":98},[],{"trials":2857,"activeCount":98},[],{"trials":2859,"activeCount":98},[],{"trials":2861,"activeCount":98},[],{"trials":2863,"activeCount":98},[],{"trials":2865,"activeCount":98},[2866],{"nctId":2867,"briefTitle":2868,"status":156,"phases":2869,"primaryCompletion":2870,"completion":2871,"start":356,"enrollment":2872,"conditions":2873,"interventions":2875},"NCT02702661","PRCT of FICB vs LAI for Hip Arthroscopy",[91],"2013-11","2014-04",46,[2874],"Femoroacetabular Impingement",[2852]]